{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:05:35Z","timestamp":1791360335495,"version":"4.3.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:00:00Z","timestamp":1421798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jhep.2015.01.018","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T05:45:35Z","timestamp":1429681535000},"page":"S76-S86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":221,"special_numbering":"S","title":["Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs"],"prefix":"10.1016","volume":"62","author":[{"given":"Stephen","family":"Locarnini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Hatzakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Shinn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.01.018_b0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jama.1965.03080070025007","article-title":"A \u201cNew\u201d antigen in leukemia sera","volume":"191","author":"Blumberg","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.01.018_b0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virusres.2007.02.021","article-title":"Hepatitis B virus genetic variability and evolution","volume":"127","author":"Kay","year":"2007","journal-title":"Virus Res"},{"key":"10.1016\/j.jhep.2015.01.018_b0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1872-034X.2009.00601.x","article-title":"Geographical and genetic diversity of the human hepatitis B virus","volume":"40","author":"Kurbanov","year":"2010","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2015.01.018_b0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.semcancer.2013.08.006","article-title":"Possible origins and evolution of the hepatitis B virus (HBV)","volume":"23","author":"Locarnini","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jhep.2015.01.018_b0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3748\/wjg.v13.i1.14","article-title":"Hepatitis B virus taxonomy and hepatitis B virus genotypes","volume":"13","author":"Schaefer","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.01.018_b0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jhep.2010.12.030","article-title":"Natural history of chronic hepatitis B in Euro-Mediterranean and African countries","volume":"55","author":"Hadziyannis","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cld.2010.05.007","article-title":"Natural history of chronic hepatitis B","volume":"14","author":"McMahon","year":"2010","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2015.01.018_b0045","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0168-8278(00)00094-5","article-title":"The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B","volume":"34","author":"Papatheodoridis","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0050","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.vaccine.2004.10.045","article-title":"Hepatitis B virus genotypes","volume":"23","author":"Kramvis","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2015.01.018_b0055","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20365","article-title":"A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D","volume":"40","author":"Tanaka","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.018_b0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.01.018_b0065","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.01.018_b0070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.018_b0075","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.01.018_b0080","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2015.01.018_b0085","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/cid\/cis1013","article-title":"The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call","volume":"56","author":"Tedder","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.01.018_b0090","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/eurpub\/cks067","article-title":"Changing epidemiology of hepatitis B and migration\u2013a comparison of six Northern and North-Western European countries","volume":"23","author":"Chu","year":"2013","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.jhep.2015.01.018_b0095","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.01.018_b0100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","article-title":"Global control of hepatitis B virus infection","volume":"2","author":"Kao","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.01.018_b0105","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jhep.2009.01.002","article-title":"Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B","volume":"50","author":"Chen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0140-6736(81)91908-5","article-title":"Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal)","volume":"1","author":"Maupas","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.01.018_b0115","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States","volume":"303","author":"Szmuness","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.018_b0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2015.01.018_b0125","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jama.1990.03440090052025","article-title":"The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies","volume":"263","author":"Alter","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.01.018_b0130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1988.03720030025027","article-title":"Cost-effectiveness of prenatal screening and immunization for hepatitis B virus","volume":"259","author":"Arevalo","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.01.018_b0135","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/jama.1987.03390190075023","article-title":"A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers","volume":"257","author":"Chen","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.01.018_b0140","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/bmj.314.7086.1033","article-title":"Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board","volume":"314","author":"Van Damme","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2015.01.018_b0145","first-page":"1057","article-title":"Hepatitis B vaccine in the expanded programme of immunisation: the Gambian experience. The Gambia Hepatitis Study Group","volume":"1","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.01.018_b0150","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/infdis\/171.2.290","article-title":"Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in Indonesia","volume":"171","author":"Ruff","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2015.01.018_b0155","series-title":"Hepatitis B virus infection, its sequelae and prevention in Taiwan","author":"Chen","year":"1987"},{"key":"10.1016\/j.jhep.2015.01.018_b0160","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.24500","article-title":"Fighting against viral hepatitis: lessons from Taiwan","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.018_b0165","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2012.05.021","article-title":"Minimization of hepatitis B infection by a 25-year universal vaccination program","volume":"57","author":"Ni","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0170","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mpd.2001.116277","article-title":"Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan","volume":"139","author":"Kao","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2015.01.018_b0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.20006","article-title":"Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15years after universal hepatitis B vaccination","volume":"39","author":"Chen","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.018_b0180","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.01.018_b0185","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/infdis\/jir852","article-title":"Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan","volume":"205","author":"Su","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2015.01.018_b0190","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1086\/528687","article-title":"Acute hepatitis B 14years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges","volume":"46","author":"Mele","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.01.018_b0195","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archpedi.157.10.1025","article-title":"The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy","volume":"157","author":"Bhimma","year":"2003","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jhep.2015.01.018_b0200","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s00467-003-1277-z","article-title":"The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis","volume":"18","author":"Xu","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jhep.2015.01.018_b0205","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1542\/peds.2010-3137","article-title":"Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy","volume":"128","author":"Liao","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jhep.2015.01.018_b0210","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8","article-title":"Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma","volume":"64","author":"Chang","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2015.01.018_b0215","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.018_b0220","first-page":"57","article-title":"Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination","volume":"12","author":"Lee","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jhep.2015.01.018_b0225","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jnci\/djp288","article-title":"Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study","volume":"101","author":"Chang","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2015.01.018_b0230","first-page":"385","article-title":"Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma","volume":"25","author":"Li","year":"2004","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"10.1016\/j.jhep.2015.01.018_b0235","first-page":"507","article-title":"Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program","volume":"9","author":"Wichajarn","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jhep.2015.01.018_b0240","first-page":"2205","article-title":"Hepatitis B vaccination and liver cancer mortality reduction in Korean children and adolescents","volume":"12","author":"Gwack","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jhep.2015.01.018_b0245","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10552-010-9721-4","article-title":"Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers","volume":"22","author":"Tajiri","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jhep.2015.01.018_b0250","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hep.24442","article-title":"Elimination of hepatocellular carcinoma and acute hepatitis B in children 25years after a hepatitis B newborn and catch-up immunization program","volume":"54","author":"McMahon","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.018_b0255","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/carcin\/bgt007","article-title":"Dramatic reduction of liver cancer incidence in young adults: 28year follow-up of etiological interventions in an endemic area of China","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhep.2015.01.018_b0260","doi-asserted-by":"crossref","first-page":"e75775","DOI":"10.1371\/journal.pone.0075775","article-title":"20-years of population-based cancer registration in hepatitis B and liver cancer prevention in the Gambia, West Africa","volume":"8","author":"Bah","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.01.018_b0265","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.gastro.2011.12.035","article-title":"Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV","volume":"142","author":"Chen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.01.018_b0270","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2013.02.015","article-title":"Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention","volume":"59","author":"Wen","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0275","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2893.2008.01067.x","article-title":"Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection","volume":"16","author":"Chotiyaputta","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.01.018_b0280","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2014.04.038","article-title":"Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus","volume":"61","author":"Greenup","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0285","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jhep.2011.02.032","article-title":"A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection","volume":"55","author":"Han","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0290","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2893.2008.01056.x","article-title":"Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study","volume":"16","author":"Xu","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.01.018_b0295","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0300","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2015.01.018_b0305","doi-asserted-by":"crossref","first-page":"384","DOI":"10.7326\/0003-4819-142-5-200503010-00014","article-title":"Long-term protection of hepatitis B vaccine: lessons from Alaskan experience after 15 years","volume":"142","author":"Chen","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2015.01.018_b0310","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/gutjnl-2011-300832","article-title":"Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B","volume":"61","author":"Tamada","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.01.018_b0315","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.amjmed.2008.09.002","article-title":"Universal hepatitis B vaccination: killing 2 birds with 1 stone","volume":"121","author":"Kao","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2015.01.018_b0320","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ajg.2013.111","article-title":"Oral nucleoside\/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B","volume":"108","author":"Fung","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.01.018_b0325","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.018_b0330","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1478-3231.2012.02805.x","article-title":"Natural history of chronic hepatitis B: what exactly has REVEAL revealed?","volume":"32","author":"Iloeje","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.01.018_b0335","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cgh.2013.04.036","article-title":"Management of hepatitis B: our practice and how it relates to the guidelines","volume":"12","author":"Yapali","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0340","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cgh.2014.08.024","article-title":"Is it more cost effective for patients with chronic hepatitis B to have a trial of interferon before considering nucleos(t)ide analogue therapy?","volume":"13","author":"Konerman","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0345","doi-asserted-by":"crossref","first-page":"f3893","DOI":"10.1136\/bmj.f3893","article-title":"Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance","volume":"346","author":"Sarri","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2015.01.018_b0350","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.01.018_b0355","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.018_b0360","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2013-306409","article-title":"Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease","author":"Cho","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.01.018_b0365","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.018_b0370","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.01.018_b0375","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-0033-1345713","article-title":"New therapeutic targets and drugs for the treatment of chronic hepatitis B","volume":"33","author":"Fletcher","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2015.01.018_b0380","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1128\/JVI.03478-13","article-title":"Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide","volume":"88","author":"Yan","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2015.01.018_b0385","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.01.018_b0390","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2013.06.029","article-title":"Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia","volume":"59","author":"Chen","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.018_b0395","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3851\/IMP2654","article-title":"Mortality due to viral hepatitis in the Global Burden of Disease Study 2010: new evidence of an urgent global public health priority demanding action","volume":"18","author":"Cowie","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.01.018_b0400","doi-asserted-by":"crossref","first-page":"691","DOI":"10.7326\/0003-4819-77-5-691","article-title":"Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors","volume":"77","author":"Alter","year":"1972","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2015.01.018_b0405","unstructured":"World Hepatitis Alliance Viral Hepatitis: Global Policy; 2010."},{"key":"10.1016\/j.jhep.2015.01.018_b0410","unstructured":"World Health Assembly. Viral Hepatitis Resolution WHA63.18; 2010."},{"key":"10.1016\/j.jhep.2015.01.018_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2011.01499.x","article-title":"The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference","volume":"18","author":"Hatzakis","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.01.018_b0420","unstructured":"World Health Organisation. Prevention and Control of Viral Hepatitis Infection: Framework for Global Action; 2012."},{"key":"10.1016\/j.jhep.2015.01.018_b0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvh.12120","article-title":"The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference","volume":"20","author":"Hatzakis","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.01.018_b0430","unstructured":"World Health Assembly. Viral Hepatitis Resolution WHA676; 2014."},{"key":"10.1016\/j.jhep.2015.01.018_b0435","article-title":"Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries","author":"Dan","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2015.01.018_b0440","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3851\/IMP2719","article-title":"Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies","volume":"19","author":"Arama","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.01.018_b0445","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3851\/IMP2482","article-title":"Patient preferences for hepatitis B therapy","volume":"18","author":"Lim","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.01.018_b0450","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.01.018_b0455","unstructured":"World Hepatitis Alliance. Viral Hepatitis: Global Policy; 2013."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815000495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815000495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T18:35:55Z","timestamp":1651775755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815000495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0168827815000495"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.01.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}